Alector, Cassava and Annovis play up mixed data in dementia, but the markets aren’t buying it.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
But this week three transactions did squeak through.
But with Derm Assist available free, how will the company make money?
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.